SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan� (“i2.JP”; Website: https://www.i2jp.net/en/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).
i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.
Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.
By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.
Contacts
Lightnix Inc.
Akihiro ISUMI, General Manager
+81-48-951-3637
info@lightnix.jp
https://www.lightnix.jp/en/
SEOUL, SOUTH KOREA - Media OutReach Newswire - 16 December 2025 - St. George’s University…
HONG KONG SAR - Media OutReach Newswire - 15 December 2025 - The Court of…
Red Bull Malaysia celebrates the teams' outstanding performance at the 2025 PETRONAS MAM Malaysian Cub…
BEIJING, CHINA - Media OutReach Newswire - 15 December 2025 - CGTN will release its…
SUBANG, INDONESIA - Media OutReach Newswire - 15 December 2025 - VinFast officially inaugurated its…
SINGAPORE - Media OutReach Newswire - 15 December 2025 - Fast Track Events (FTE), a…